News brief
On September 26, 2026, Beijing-based Huayuan Zhiyin, an AI virtual-cell technology developer, completed an equity investment from the Global Health Industry Innovation Center. The company builds AI-driven virtual cell models to accelerate biomedical research.
Connected profiles
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年9月26日，据公开报道，北京AI虚拟细胞技术研发商华源智因完成一笔股权投资，投资方为全球健康产业创新中心。公司致力于用AI构建虚拟细胞模型，加速生物医学研究。